Review
Immunology
Ali Akbar Samadani, Arman Keymoradzdeh, Shima Shams, Armin Soleymanpour, Ali Rashidy-Pour, Houman Hashemian, Sogand Vahidi, Seyedeh Elham Norollahi
Summary: CAR T-cell therapy is a promising immunotherapy for cancer with the potential to treat a variety of solid tumors. By modifying T cells with CAR, it is possible to effectively eliminate certain cancers. Strategies for investigating risks and mitigating off-tumor consequences are crucial, and successful CAR T-cell therapy protocols can enhance the efficacy and safety of treatment.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Article
Cell Biology
Zhenzhen Hui, Jiali Zhang, Yulin Ren, Xiaoling Li, Cihui Yan, Wenwen Yu, Tao Wang, Shanshan Xiao, Yulong Chen, Ran Zhang, Feng Wei, Jian You, Xiubao Ren
Summary: The study found that the synergistic increase of B cells and CD4(+) T cells is associated with positive therapeutic response in neoadjuvant chemoimmunotherapy. B cell IgG subclasses IgG1 and IgG3 play critical roles in anti-tumor immune responses in tumor lesions, and this process is driven by increased IL-21 secretion by infiltrated T follicular helper (Tfh) cells after neoadjuvant chemoimmunotherapy.
CELL DEATH & DISEASE
(2022)
Review
Oncology
Rebecca C. Abbott, Hannah E. Hughes-Parry, Misty R. Jenkins
Summary: Genetically engineered T cells have been effective in treating hematological malignancies, but not in solid tumors. Biological logic gating in T cells is a promising approach to overcome the challenges associated with solid tumors.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Biochemistry & Molecular Biology
Kue Peng Lim, Nur Syafinaz Zainal
Summary: With the regulatory approval of Provenge and T-VEC for the treatment of metastatic prostate cancer and advanced melanoma respectively, and other promising clinical trials outcomes, cancer vaccine is gaining prominence as a cancer therapeutic agent.
FRONTIERS IN MOLECULAR BIOSCIENCES
(2021)
Article
Immunology
Andrew Chow, Fathema Z. Uddin, Michael Liu, Anton Dobrin, Barzin Y. Nabet, Levi Mangarin, Yonit Lavin, Hira Rizvi, Sam E. Tischfield, Alvaro Quintanal-Villalonga, Joseph M. Chan, Nisargbhai Shah, Viola Allaj, Parvathy Manoj, Marissa Mattar, Maximiliano Meneses, Rebecca Landau, Mariana Ward, Amanda Kulick, Charlene Kwong, Matthew Wierzbicki, Jessica Yavner, Jacklynn Egger, Shweta S. Chavan, Abigail Farillas, Aliya Holland, Harsha Sridhar, Metamia Ciampricotti, Daniel Hirschhorn, Xiangnan Guan, Allison L. Richards, Glenn Heller, Jorge Mansilla-Soto, Michel Sadelain, Christopher A. Klebanoff, Matthew D. Hellmann, Triparna Sen, Elisa de Stanchina, Jedd D. Wolchok, Taha Merghoub, Charles M. Rudin
Summary: Improved identification of anti-tumor T cells is crucial for cancer immunotherapy. CD39 expression is a promising indicator of tumor-reactive CD8+ T cells. A comprehensive analysis of CD39 expression in human lung cancer showed that CD39 enriches for exhausted, tumor-reactive, and clonally expanded CD8+ T cells. The presence of CD39+ CD8+ T cells is weakly associated with tumoral features, and their frequency can be increased by immune checkpoint blockade. Higher baseline frequency of CD39+ CD8+ T cells predicts improved clinical outcomes from immune checkpoint blockade therapy.
Review
Immunology
Isis Benoit-Lizon, Lionel Apetoh
Summary: CD4 T cell effector subsets have a significant impact on cancer progression and the efficacy of immune checkpoint inhibitors. T(H)9 cells have shown superior antimelanoma activity, but further research is needed to understand their mechanisms and potential in treating other types of cancer.
SEMINARS IN IMMUNOLOGY
(2021)
Article
Biology
Alyssa Vito, Omar Salem, Nader El-Sayes, Ian P. MacFawn, Ana L. Portillo, Katy Milne, Danielle Harrington, Ali A. Ashkar, Yonghong Wan, Samuel T. Workenhe, Brad H. Nelson, Tullia C. Bruno, Karen L. Mossman
Summary: The combination immunotherapy platform in triple negative breast cancer increases tumor-infiltrating lymphocytes and improves response to immune checkpoint blockade. B cells play a crucial role in antitumor immunity and modulate myeloid-derived suppressor cells.
COMMUNICATIONS BIOLOGY
(2021)
Review
Oncology
Myriam Ben Khelil, Yann Godet, Syrine Abdeljaoued, Christophe Borg, Olivier Adotevi, Romain Loyon
Summary: CD4(+) T cells play a crucial role in antitumor immunity, either by promoting or suppressing cytotoxic T cell responses. This review highlights the role of CD4(+) T subsets within the tumor microenvironment and discusses the latest developments in modulating CD4(+) T responses for cancer immunotherapy and improving cancer strategies.
Review
Immunology
David Y. Oh, Lawrence Fong
Summary: Cytotoxic CD4(+) T cells play important roles in both cancer and non-cancer environments, where they can directly kill cancer cells. They are also found in situations like infection and autoimmunity. The cytolytic mechanisms of cytotoxic CD4(+) T cells vary across different disease states.
Article
Oncology
Dominik Lock, Razieh Monjezi, Caroline Brandes, Stephan Bates, Simon Lennartz, Karin Teppert, Leon Gehrke, Rafailla Karasakalidou-Seidt, Teodora Lukic, Marco Schmeer, Martin Schleef, Niels Werchau, Matthias Eyrich, Mario Assenmacher, Andrew Kaiser, Sabrina Prommersberger, Thomas Schaser, Michael Hudecek
Summary: We established an automated manufacturing process for CAR T cells using the CliniMACS Prodigy platform, which is scaled to provide therapeutic doses and achieves gene-transfer with virus-free Sleeping Beauty transposition.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Immunology
Zhangyan Guo, Rui Zhang, An-Gang Yang, Guoxu Zheng
Summary: Finding effective treatments for cancer remains a challenge. Recent studies have discovered the diverse mechanisms of tumor evasion and abnormal expression of immune checkpoint molecules on different immune cells. Understanding the enhanced expression of checkpoint molecules and their consequences on immune effector functions is crucial for immunotherapy using checkpoint inhibitors.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Mark A. J. M. Hendriks, Isabel Britsch, Xiurong Ke, Anne P. van Wijngarden, Douwe F. Samplonius, Emily M. Ploeg, Wijnand Helfrich
Summary: Cancer cells use overexpression of CD47 to inhibit immune cell clearance and new antigen processing, as well as to evade T cell immune attack through CD47 expression. However, knocking out CD47 makes cancer cells more susceptible to T cell attack. A bispecific antibody has been designed to overcome CD47-mediated immune resistance and enhance cancer cell susceptibility to T cell attack.
Article
Chemistry, Multidisciplinary
Min-Ren Chiang, Wei-Ting Shen, Pin-Xuan Huang, Kang-Li Wang, Wei-Han Weng, Chien-Wen Chang, Wen-Hsuan Chiang, Yu-Chen Liu, Shing-Jyh Chang, Shang-Hsiu Hu
Summary: T lymphocytes physically interact with cancer cells to suppress metastases. The tumor immune privilege and heterogeneity limit immune cell infiltration, especially in invasive metastatic clusters. A catalytic antigen-capture sponge (CAS) containing catechol-functionalized copper-based metal organic framework (MOF) and chloroquine (CQ) is reported for programming T cell infiltration. CAS accumulates at the tumor and disrupts intracellular redox potential, reducing glutathione (GSH) levels. CQ inhibits autophagy, leading to breakdown of self-defense mechanisms and prolonged immune activation. CAS serves as an antigen reservoir and promotes immune cell accumulation, hindering metastatic tumors.
JOURNAL OF CONTROLLED RELEASE
(2023)
Review
Biochemistry & Molecular Biology
Shilpi Singh, Debashis Barik, Ananta Prasad Arukha, Sujata Prasad, Iteeshree Mohapatra, Amar Singh, Gatikrushna Singh
Summary: This article introduces strategies to modify immune cells within the tumor microenvironment using small molecules, potentially revolutionizing therapeutic interventions and enhancing the anti-tumor response.
Article
Oncology
Alphonse Charbel, Luca Tavernar, Thomas Albrecht, Fritz Brinkmann, Joanne Verheij, Eva Roos, Monika Nadja Vogel, Bruno Kohler, Christoph Springfeld, Alexander Brobeil, Peter Schirmacher, Stephan Singer, Arianeb Mehrabi, Stephanie Roessler, Benjamin Goeppert
Summary: This study provides a comprehensive characterization of the inflammatory microenvironment in precursor lesions of biliary tract carcinoma (BTC). The results show distinct immune cell variations in intraductal papillary neoplasms (IPN) and biliary epithelial neoplasia (BilIN), with different dynamics during biliary carcinogenesis.
BRITISH JOURNAL OF CANCER
(2022)
Letter
Medical Laboratory Technology
Ainsleigh J. Hill, Chaoran Zhang, Manabu Kusakabe, Kevin Gowing, Xuehai Wang, Ryan R. Brinkman, Andrew P. Weng, Jeffrey W. Craig
CYTOMETRY PART B-CLINICAL CYTOMETRY
(2021)
Article
Biochemical Research Methods
Kim R. M. Blenman, Josef Spidlen, David R. Parks, Wayne Moore, Adam Treister, Robert Leif, Chris Bray, Michael Goldberg, Ryan Brinkman
Summary: With the advancement of microscopy imaging and flow cytometry, the number of probes has increased rapidly, leading to the creation of arbitrary synonyms for probe tags in publications and software, causing issues in readability and data analysis. The development of a standardized nomenclature for probe tags is essential for ensuring data quality and facilitating data integration across multiple platforms.
Article
Biochemical Research Methods
Josef Spidlen, Wayne Moore, David Parks, Michael Goldberg, Kim Blenman, James S. Cavenaugh, Ryan Brinkman
Summary: FCS 3.2 is a revised flow cytometry data standard that aims to capture instrument conditions and measurement features more precisely, providing a uniform file format. The new version supports mixed data types to efficiently handle new types of data and use cases, but is incompatible with existing FCS file readers.
Article
Multidisciplinary Sciences
Zhaoyu Sun, Richard Nyberg, Yaping Wu, Brady Bernard, William L. Redmond
Summary: The TSA Opal multiplex immunohistochemistry protocol has been used to characterize immune infiltration in human cancers. Two improved protocols were developed for a 7-color panel with 6 biomarkers, showing that antigen retrieval method is crucial for staining intensity. The study demonstrated the importance of proper antigen retrieval method in multiplex immunohistochemistry and its impact on individual biomarker staining intensity.
Article
Oncology
Dana A. Emerson, Annah S. Rolig, William L. Redmond
Summary: The combination of CTLA-4 blockade and OX40-specific monoclonal antibody has been shown to enhance antitumor immunity by upregulating Eomes expression in CD8(+) T cells. Further modulation of Eomes expression through ITK signaling with ibrutinib can lead to enhanced tumor regression and improved survival, making the combination therapy a potential triple therapy option for improving immunotherapy efficacy.
CANCER IMMUNOLOGY RESEARCH
(2021)
Article
Biochemical Research Methods
Alice Yue, Cedric Chauve, Maxwell W. Libbrecht, Ryan R. Brinkman
Summary: The study introduces a new cell population score called SpecEnr and a method for discovering candidate biomarkers from flow cytometry data. This approach identifies driver cell populations associated with sample classes and provides easily interpretable results through lattice-based visualization tools. The method is implemented in the R package flowGraph, which is freely available on GitHub and BioConductor.
Article
Oncology
Yoshinobu Koguchi, Noriko Iwamoto, Takashi Shimada, Shu-Ching Chang, John Cha, Brendan D. Curti, Walter J. Urba, Brian D. Piening, William L. Redmond
Summary: Trough levels of ipilimumab may be a useful biomarker for long-term survival of patients with advanced melanoma, with associations with CXCL11 and sCD25 suggesting a baseline-driven E-R relationship, while associations with CRP and IL-6 levels indicate response-driven E-R relationship.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Brie Chun, Joanna Pucilowska, ShuChing Chang, Isaac Kim, Benjamin Nikitin, Yoshinobu Koguchi, William L. Redmond, Brady Bernard, Venkatesh Rajamanickam, Nathan Polaske, Paul A. Fields, Valerie Conrad, Mark Schmidt, Walter J. Urba, Alison K. Conlin, Heather L. McArthur, David B. Page
Summary: This study investigates the effects of pembrolizumab combined with paclitaxel or capecitabine on T-cell subsets in triple-negative breast cancer patients. The results show that these treatments result in similar lymphodepletions across peripheral T-cell subsets and do not alter T-cell clonal diversity. The findings contribute to our understanding of the impact of chemoimmunotherapy on the immune system.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Oncology
Rashi Yadav, William L. Redmond
Summary: This review discusses the impact of OX40 agonists on T cell function and the therapeutic potential of OX40 agonists alone or in conjunction with ICB for patients with advanced malignancies.
CURRENT ONCOLOGY REPORTS
(2022)
Article
Oncology
Annah S. Rolig, Daniel C. Rose, Grace Helen McGee, Werner Rubas, Saul Kivimae, William L. Redmond
Summary: This study aims to evaluate whether intratumoral NKTR-262 combined with systemic BEMPEG treatment can improve tumor-specific immunity and survival. The results showed that BEMPEG+NKTR-262 significantly improved survival and inhibited tumor growth by expanding activated CD8(+) T cells and enhancing cytolytic function.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Immunology
Yoshinobu Koguchi, William L. Redmond
Summary: While immune checkpoint blockade has revolutionized cancer treatment, the majority of patients do not benefit from it. Various efforts have been made to interrogate the immune system using different biospecimens, technologies, and disciplines, but consistent biomarkers of response have remained elusive. Pharmacokinetics studies, however, provide critical information and may reveal useful biomarkers.
IMMUNOLOGICAL INVESTIGATIONS
(2022)
Article
Biochemical Research Methods
Daniel C. Rose, Annah S. Rolig, William L. Redmond
Summary: This article describes a flow cytometry panel specifically designed to assess the expression of activation and exhaustion markers in expanding lymphocyte populations in tumor-bearing mice. It enables the assessment of multiple functional states and immune checkpoint markers across various immune cell subsets in murine whole blood, lymph nodes, and tumor.
Article
Oncology
David B. Page, Joanna Pucilowska, Brie Chun, Isaac Kim, Katherine Sanchez, Nicole Moxon, Staci Mellinger, Yaping Wu, Yoshinobu Koguchi, Valerie Conrad, William L. Redmond, Maritza Martel, Zhaoyu Sun, Mary B. Campbell, Alison Conlin, Anupama Acheson, Reva Basho, Philomena McAndrew, Mary El-Masry, Dorothy Park, Laura Bennetts, Robert S. Seitz, Tyler J. Nielsen, Kimberly McGregor, Venkatesh Rajamanickam, Brady Bernard, Walter J. Urba, Heather L. McArthur
Summary: Chemoimmunotherapy with anti-PD-1/L1 and cytotoxic chemotherapy is a promising treatment for triple-negative breast cancer, but further research is needed to determine the optimal chemotherapy regimen and biomarkers for patient selection. This study investigated the safety and efficacy of pembrolizumab in combination with paclitaxel or capecitabine, and found that both regimens were safe and clinically active.
Article
Oncology
Elizabeth R. Sturgill, Annah S. Rolig, Stefanie N. Linch, Courtney Mick, Melissa J. Kasiewicz, Zhaoyu Sun, Peter G. Traber, Harold Shlevin, William L. Redmond
Summary: Combining Gal-3 inhibition with aOX40 therapy promotes tumor regression and increases survival by reducing M-MDSC-mediated immune suppression, enhancing CD8(+) T cell recruitment, leading to improved tumor regression and survival.
